IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer

Gut

Volumn 67, Issue 2, 2018, Pages 320-332

  MacE, Thomas A ^a   Shakya, Reena ^b   Pitarresi, Jason R ^a   Swanson, Benjamin ^a   McQuinn, Christopher W ^a   Loftus, Shannon ^a   Nordquist, Emily ^a   Cruz Monserrate, Zobeida ^a   Yu, Lianbo ^a   Young, Gregory ^a   Zhong, Xiaoling ^a   Zimmers, Teresa A ^a   Ostrowski, Michael C ^a   Ludwig, Thomas ^a   Bloomston, Mark ^b   Bekaii Saab, Tanios ^c   Lesinski, Gregory B ^d  

^a OHIO STATE UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c MAYO CLINIC   (United States)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

IMMUNOTHERAPY; INTERLEUKINS; PANCREATIC CANCER

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; ANTINEOPLASTIC MONOCLONAL ANTIBODY; BRCA2 PROTEIN; CD4 ANTIGEN; CD8 ANTIGEN; CYTOKINE; HERMES ANTIGEN; K RAS PROTEIN; L SELECTIN; MONOCLONAL ANTIBODY IL 6; MONOCLONAL ANTIBODY PD L1; TRANSCRIPTION FACTOR PDX 1; TRYPTOPHAN; UNCLASSIFIED DRUG; ACTIN; ALPHA-SMOOTH MUSCLE ACTIN, MOUSE; ANTINEOPLASTIC AGENT; CD274 PROTEIN, MOUSE; HYALURONIC ACID BINDING PROTEIN; IMMUNOLOGICAL ANTINEOPLASTIC AGENT; INTERLEUKIN 6; INTERLEUKIN-6, MOUSE; JANUS KINASE; PROGRAMMED DEATH 1 LIGAND 1; STAT PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG EFFICACY; DRUG TARGETING; EFFECTOR CELL; FEMALE; FLOW CYTOMETRY; GENETICALLY ENGINEERED MOUSE STRAIN; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOMODULATION; IMMUNOPHENOTYPING; IN VIVO STUDY; LYMPHOCYTIC INFILTRATION; MONOTHERAPY; MOUSE; MURINE MODEL; NONHUMAN; OVERALL SURVIVAL; PANC02 CELL LINE; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PANCREATIC STELLATE CELL; PRIORITY JOURNAL; PROTEIN LOCALIZATION; STROMAL TUMOR CELL LINE; T CELL DEPLETION; T LYMPHOCYTE; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; DISEASE EXACERBATION; DISEASE MODEL; DRUG SCREENING; IMMUNOLOGY; METABOLISM; PANCREAS CARCINOMA; PANCREAS TUMOR; SURVIVAL RATE; TH1 CELL; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT;

ACTINS; ANIMALS; ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; B7-H1 ANTIGEN; CARCINOMA, PANCREATIC DUCTAL; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; FEMALE; HUMANS; HYALURONAN RECEPTORS; INTERLEUKIN-6; JANUS KINASES; L-SELECTIN; LYMPHOCYTES, TUMOR-INFILTRATING; MICE; MICE, INBRED C57BL; PANCREATIC NEOPLASMS; PANCREATIC STELLATE CELLS; STAT TRANSCRIPTION FACTORS; SURVIVAL RATE; TH1 CELLS; TUMOR MICROENVIRONMENT; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84994516325     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2016-311585     Document Type: Article

References (49)

1. Rahib L, Smith BD, Aizenberg R, et al. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res 2014;74:2913-21.
2. Vincent A, Herman J, Schulick R, et al. Pancreatic cancer. Lancet 2011;378:607-20.
3. Al-Hajeili M, Azmi AS, Choi M. Nab-paclitaxel: potential for the treatment of advanced pancreatic cancer. Onco Targets Ther 2014;7:187-92.
4. Zhang Y, Yan W, Collins MA, et al. Interleukin-6 is required for pancreatic cancer progression by promoting MAPK signaling activation and oxidative stress resistance. Cancer Res 2013;73:6359-74.
5. Lesina M, Kurkowski MU, Ludes K, et al. Stat3/Socs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer. Cancer Cell 2011;19:456-69.
6. Rose-John S, Scheller J, Elson G, et al. Interleukin-6 biology is coordinated by membrane-bound and soluble receptors: role in inflammation and cancer. J Leukoc Biol 2006;80:227-36.
7. Fisher DT, Appenheimer MM, Evans SS. The two faces of IL-6 in the tumor microenvironment. Semin Immunol 2014;26:38-47.
8. Scheller J, Chalaris A, Schmidt-Arras D, et al. The pro-and anti-inflammatory properties of the cytokine interleukin-6. Biochim Biophys Acta 2011;1813:878-88.
9. Corcoran RB, Contino G, Deshpande V, et al. STAT3 plays a critical role in KRAS-induced pancreatic tumorigenesis. Cancer Res 2011;71:5020-9.
10. Scholz A, Heinze S, Detjen KM, et al. Activated signal transducer and activator of transcription 3 (STAT3) supports the malignant phenotype of human pancreatic cancer. Gastroenterology 2003;125:891-905.
11. Gabitass RF, Annels NE, Stocken DD, et al. Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13. Cancer Immunol Immunother 2011;60:1419-30.
12. Markowitz J, Brooks TR, Duggan MC, et al. Patients with pancreatic adenocarcinoma exhibit elevated levels of myeloid-derived suppressor cells upon progression of disease. Cancer Immunol Immunother 2015;64:149-59.
13. Mundy-Bosse BL, Young GS, Bauer T, et al. Distinct myeloid suppressor cell subsets correlate with plasma IL-6 and IL-10 and reduced interferon-alpha signaling in CD4+ T cells from patients with GI malignancy. Cancer Immunol Immunother 2011;60:1269-79.
14. Mace TA, Bloomston M, Lesinski GB. Pancreatic cancer-associated stellate cells: a viable target for reducing immunosuppression in the tumor microenvironment. Oncoimmunology 2013;2:e24891.
15. Goumas FA, Holmer R, Egberts JH, et al. Inhibition of IL-6 signaling significantly reduces primary tumor growth and recurrencies in orthotopic xenograft models of pancreatic cancer. Int J Cancer 2015;137:1035-46.
16. Farren MR, Mace TA, Geyer S, et al. Systemic immune activity predicts overall survival in treatment naive patients with metastatic pancreatic cancer. Clin Cancer Res 2016;22:2565-74.
17. Jiang X, Zhou J, Giobbie-Hurder A, et al. The activation of MAPK in melanoma cells resistant to BRAF inhibition promotes PD-L1 expression that is reversible by MEK and PI3K inhibition. Clin Cancer Res 2013;19:598-609.
18. Chen L, Han X. Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future. J Clin Invest 2015;125:3384-91.
19. Freeman GJ, Long AJ, Iwai Y, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 2000;192:1027-34.
20. Goldberg MV, Maris CH, Hipkiss EL, et al. Role of PD-1 and its ligand, B7-H1, in early fate decisions of CD8 T cells. Blood 2007;110:186-92.
21. Topalian SL, Drake CG, Pardoll DM. Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol 2012;24:207-12.
22. Duluc D, Delneste Y, Tan F, et al. Tumor-associated leukemia inhibitory factor and IL-6 skew monocyte differentiation into tumor-associated macrophage-like cells. Blood 2007;110:4319-30.
23. Marigo I, Bosio E, Solito S, et al. Tumor-induced tolerance and immune suppression depend on the C/EBPbeta transcription factor. Immunity 2010;32:790-802.
24. Tsukamoto H, Nishikata R, Senju S, et al. Myeloid-derived suppressor cells attenuate TH1 development through IL-6 production to promote tumor progression. Cancer Immunol Res 2013;1:64-76.
25. Ma Y, Hwang RF, Logsdon CD, et al. Dynamic mast cell-stromal cell interactions promote growth of pancreatic cancer. Cancer Res 2013;73:3927-37.
26. Ludwig T, Fisher P, Murty V, et al. Development of mammary adenocarcinomas by tissue-specific knockout of Brca2 in mice. Oncogene 2001;20:3937-48.
27. Guenterberg KD, Lesinski GB, Mundy-Bosse BL, et al. Enhanced anti-tumor activity of interferon-alpha in SOCS1-deficient mice is mediated by CD4+ and CD8+ T cells. Cancer Immunol Immunother 2011;60:1281-8.
28. Sartor MA, Tomlinson CR, Wesselkamper SC, et al. Intensity-based hierarchical Bayes method improves testing for differentially expressed genes in microarray experiments. BMC Bioinformatics 2006;7:538.
29. Gordon A, Glazko G, Qiu X, et al. Control of the Mean Number of False Discoveries, Bonferroni and Stability of Multiple Testing. Ann Appl Stat 2007;1:179-90.
30. Slinker BK. The statistics of synergism. J Mol Cell Cardiol 1998;30:723-31.
31. Boj SF, Hwang CI, Baker LA, et al. Organoid models of human and mouse ductal pancreatic cancer. Cell 2015;160:324-38.
32. Collignon A, Perles-Barbacaru AT, Robert S, et al. A pancreatic tumor-specific biomarker characterized in humans and mice as an immunogenic onco-glycoprotein is efficient in dendritic cell vaccination. Oncotarget 2015;6:23462-79.
33. Pilon-Thomas S, Nelson N, Vohra N, et al. Murine pancreatic adenocarcinoma dampens SHIP-1 expression and alters MDSC homeostasis and function. PLoS One 2011;6:e27729.
34. Suzuki K, Ogura M, Abe Y, et al. Phase 1 study in Japan of siltuximab, an anti-IL-6 monoclonal antibody, in relapsed/refractory multiple myeloma. Int J Hematol 2015;101:286-94.
35. San-Miguel J, Bladé J, Shpilberg O, et al. Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma. Blood 2014;123:4136-42.
36. Hunsucker SA, Magarotto V, Kuhn DJ, et al. Blockade of interleukin-6 signalling with siltuximab enhances melphalan cytotoxicity in preclinical models of multiple myeloma. Br J Haematol 2011;152:579-92.
37. Dijkgraaf EM, Santegoets SJ, Reyners AK, et al. A phase I trial combining carboplatin/doxorubicin with tocilizumab, an anti-IL-6R monoclonal antibody, and interferon-2b in patients with recurrent epithelial ovarian cancer. Ann Oncol 2015;26:2141-9.
38. Bayne LJ, Beatty GL, Jhala N, et al. Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer. Cancer Cell 2012;21:822-35.
39. Neesse A, Michl P, Frese KK, et al. Stromal biology and therapy in pancreatic cancer. Gut 2011;60:861-8.
40. Fearon DT. The carcinoma-associated fibroblast expressing fibroblast activation protein and escape from immune surveillance. Cancer Immunol Res 2014;2:187-93.
41. Feig C, Jones JO, Kraman M, et al. Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer. Proc Natl Acad Sci USA 2013;110:20212-17.
42. Lo A, Wang LC, Scholler J, et al. Tumor-Promoting Desmoplasia Is Disrupted by Depleting FAP-Expressing Stromal Cells. Cancer Res 2015;75:2800-10.
43. Rhim AD, Oberstein PE, Thomas DH, et al. Stromal Elements Act to Restrain, Rather Than Support, Pancreatic Ductal Adenocarcinoma. Cancer Cell 2014;25:735-47.
44. Lee JJ, Perera RM, Wang H, et al. Stromal response to Hedgehog signaling restrains pancreatic cancer progression. Proc Natl Acad Sci USA 2014;111:E3091-100.
45. Özdemir BC, Pentcheva-Hoang T, Carstens JL, et al. Depletion of Carcinoma-Associated Fibroblasts and Fibrosis Induces Immunosuppression and Accelerates Pancreas Cancer with Reduced Survival. Cancer Cell 2014;25:719-34.
46. Dodge IL, Carr MW, Cernadas M, et al. IL-6 production by pulmonary dendritic cells impedes Th1 immune responses. J Immunol 2003;170:4457-64.
47. Wang Y, van Boxel-Dezaire AH, Cheon H, et al. STAT3 activation in response to IL-6 is prolonged by the binding of IL-6 receptor to EGF receptor. Proc Natl Acad Sci USA 2013;110:16975-80.
48. Vassilakopoulou M, Avgeris M, Velcheti V, et al. Evaluation of PD-L1 Expression and Associated Tumor-Infiltrating Lymphocytes in Laryngeal Squamous Cell Carcinoma. Clin Cancer Res 2015;22:704-13.
49. Herbst RS, Soria JC, Kowanetz M, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 2014;515:563-7.